Asset Details
Do you wish to reserve the book?
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
Do you wish to request the book?
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
2014
Overview
Adoptive immunotherapy of tumors with T cells specific for the cancer-testis antigen NY-ESO-1 has shown great promise in preclinical models and in early stage clinical trials. Tumor persistence or recurrence after NY-ESO-1-specific therapy occurs, however, and the mechanisms of recurrence remain poorly defined. In a murine xenograft model of NY-ESO-1
+
multiple myeloma, we observed tumor recurrence after adoptive transfer of CD8
+
T cells genetically redirected to the prototypic NY-ESO-1
157-165
peptide presented by HLA-A*02:01. Analysis of the myeloma cells that had escaped from T-cell control revealed intact expression of
NY-ESO-1
and
B2M
, but selective, complete loss of HLA-A*02:01 expression from the cell surface. Loss of heterozygosity (LOH) in the major histocompatibility complex (MHC) involving the
HLA-A
locus was identified in the tumor cells, and further analysis revealed selective loss of the allele encoding HLA-A*02:01. Although LOH involving the MHC has not been described in myeloma patients with persistent or recurrent disease after immune therapies such as allogeneic hematopoietic cell transplantation (HCT), it has been described in patients with acute myelogenous leukemia who relapsed after allogeneic HCT. These results suggest that MHC loss should be evaluated in patients with myeloma and other cancers who relapse after adoptive NY-ESO-1-specific T-cell therapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Alleles
/ Animals
/ Antigen-Presenting Cells - immunology
/ Biomedical and Life Sciences
/ CD8-Positive T-Lymphocytes - immunology
/ Histocompatibility antigen HLA
/ Humans
/ Major histocompatibility complex
/ Mice
/ Multiple Myeloma - immunology
/ Neoplasm Proteins - immunology
/ Patients
